Recruiting

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

ClinicalTrials.gov IDNCT07241546
PhasePHASE2
Enrollment36
SponsorArrowhead Pharmaceuticals
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Asthma

About this study

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Clinically stable, mild atopic asthma (FEV1 ≥70% predicted) * Established allergy confirmed by positive skin prick test at screening * Willing and able to perform lung function tests and other study-related procedures * Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later Exclusion Criteria: * Concomitant diagnosis of a clinically important pulmonary disease other than asthma * Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma * History or current medical condition contraindicating methacholine challenge Note: Additional inclusion/exclusion criteria may apply per protocol.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.